UPDATE: 3D Systems (DDD) PT Lowered to $7 at JPMorgan, Stays Underweight Citing 'Cautious Outlook and Depressed Margins and FCF'
- Futures rise as bank fears ebb, focus shifts to key inflation data
- Google accuses Microsoft of anti-competitive Cloud practices
- Tesla urges Model 3 buyers to 'take delivery' before expected tax credit reduction
- Roku (ROKU) stock gains on plans to cut 200 jobs, 6% of workforce
- Alibaba to consider giving up control of operating companies - CEO
Get Alerts DDD Hot Sheet
7 Buy, 18 Hold, 6 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 15 | Down: 7 | New: 20
Join SI Premium – FREE
JPMorgan analyst Paul J. Chung lowered the price target on 3D Systems (NYSE: DDD) to $7.00 (from $9.00) while maintaining a Underweight rating.
The analyst comments "DDD posted mixed 3Q22 results, beating on PF EPS on light revenues. Industrial was up high-single digits CC on Aerospace and defense markets demand partially offset by softness in Auto while Healthcare was impacted by lower discretionary spend, particularly from the dental market. FY22 revenue guidance was lowered at the midpoint, though PF opex was also lowered underscoring management focus on profitability. Visibility remains limited particularly from the dental market, and PF operating profit remains in negative territory for the 3rd consecutive quarter, while FCF burn has hit $70mm YTD. Management expects gross margins to grind higher as price increases take effect, freight and component costs dissipate, and in-sourcing manufacturing benefits flow through. That said, Opex remains on the upward trajectory in FY23 given several acquisitions done over past year that provide limited revenues, so we expect PF operating profit and FCF to remain challenged here short term. Bioprinting remains a key focus for the firm, and could pay off materially longer term, as the technology broadens appeal to healthcare investors, though limited positive contribution to the P&L today. Management tone was cautiously optimistic, and sees tough near-term outlook particularly in Dental, though mentioned the firm has flexibility on opex if top line remains pressured. We cut earnings estimates accordingly with which our price target goes to $7.00 (from $9). Maintain UW."
You May Also Be Interested In
- Evercore ISI Upgrades Juniper Networks (JNPR) to Outperform
- Kuaishou Technology (1024:HK) PT Raised to HK$105 at Jefferies
- Wolverine World Wide (WWW) Announces Actions to Fuel Sweaty Betty’s Long-Term Growth
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Hot Comments
Related EntitiesJPMorgan, Raising Prices, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!